The ELC research team presented at the annual The Consortium of Multiple Sclerosis Centers – October 2021
The ELC research team presented at the annual The Consortium of Multiple Sclerosis Centers this week. ELC treated the first patient with commercial Ocrevus nationwide in 2017 and has been collecting data on Ocrevus patients in “ACAPELLA” ever since. The team presents data on ACAPELLA at CMSC and ECTRIMS annually.
NeurologyLive highlighted ACAPELLA: Real-World Experience with Ocrelizumab, Year Four Data, in an article linked here.
“Ocrelizumab and other anti-CD20 antibodies generally have an excellent safety profile. Concerns have been raised about the potential for increased risk of infection, hypogammaglobulinemia, and malignancy with long-term use. Although our hypothesis was that older and/or more disabled patients might have higher rates of AEs, thus far in our cohort of 354 patients treated with [ocrelizumab] for up to 4 years, this was not observed.”